Morphinan-derivatives for treating diabetes and related disorders
The invention relates to a morphinan-derivative that targets NMDA receptors on pancreatic islets and has the general formula (I) wherein R 1 is selected from —OH, —CO 2 H, —R 0 , —OR 0 , —OC(═O)R 0 , —OC(═O)OR 0 or —OC(═O)NHR 0 ; and R 2 is selected from —H, —R 0 , —C(═O)R 0 , —C(═O)OR 0 , —C(═O)NHR 0 or —C(═NH)—NH—C(═NH)—NH 2 ; wherein R 0 is in each case independently selected from —C 1 -C 6 -alkyl, -aryl, -heteroaryl, —C 1 -C 6 -alkyl-aryl or —C 1 -C 6 -alkyl-heteroaryl, in each case independently unsubstituted or substituted; or its physiologically acceptable salt and/or stereoisomer, including mixtures thereof in all ratios, for use in the treatment of a disease or condition, where the disease or condition is insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus, obesity, and/or diabetic nephropathy.
1. A method for treating a disease or condition, using a morphinan-derivative, comprising:
a subject seeking treatment by increasing blood insulin secretion at blood glucose concentrations elevated above normal
administering, to the subject, an effective amount of the morphinan-derivative,
wherein said morphinan-derivative is selected from the group consisting of
(+)-17-methyl-(9a-13a-14a)-morphinan-3-ol (Dextrorphan), and
(+)-3-methoxy-17-methyl-(9a-13a-14a)-morphinan (Dextromethorphan),
or a physiologically acceptable salt including mixtures thereof in all ratios,
where the disease or condition is selected from the group consisting of insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus, and/or diabetic nephropathy.
2. The method for treating a disease or condition as defined in claim 1 , wherein the morphinan-derivative is provided in a pharmaceutical dosage form.
3. The method for treating a disease or condition as defined in claim 2 , wherein the pharmaceutical dosage form is for oral administration.
4. The method for treating a disease or condition as defined in claim 3 , wherein the pharmaceutical dosage form is selected from the group consisting of capsules, tablets, powders, granules, solutions, suspensions in aqueous or non-aqueous liquids, edible foams, foam foods, oil-in-water liquid emulsions or water-in-oil liquid emulsions.
5. The method for treating a disease or condition as defined in claim 2 , wherein said subject is a human subject.
6. The method for treating a disease or condition as defined in claim 2 , wherein the pharmaceutical dosage form additionally comprises metformin.
7. The method for treating a disease or condition as defined in claim 1 further comprising:
determining that dietary management of overweight subjects and exercise alone does not result in adequate glycemic control, and
only after said determination, administering said morphinan-derivative to said overweight subjects.